



CE Marked Material
QCRSYPHC2 - Anti-Syphilis Quality Control Reagent Sample 2
NIBSC code: 17/B713-xxx
Instructions for use
(Version 4.0, Dated 20/07/2022)

This material is a self certified IVD and complies with the requirements of the "EU in vitro diagnostic medical device directive 98/79/EC"

1. INTENDED USE

This product is CE marked for use as an IVD within the UK, EU member states and EEA countries. In all other territories this product can be used for research purposes only.

This product is CE marked for use as an IVD within the UK, EU member states and EEA countries. In all other territories this product can be used for research purposes only.

Anti-Syphilis QC2 is intended for use in the internal laboratory quality control of immunoassays that detect immunity to *Treponema pallidum* infection. The anti-Syphilis QC2 should be included in each run as part of

a continuing quality control programme to monitor the performance of the assay. Data obtained with the anti-Syphilis QC2 can be used to construct quality control charts that can be visually monitored each time the assay is

run, to check for consistency of performance of the assay. Examples of

how these charts are constructed and used have been described elsewhere.

Anti-Syphilis QC2 is NOT INTENDED TO BE USED TO COMPARE THE SENSITIVITY OF PARTICULAR ASSAYS.

2. CAUTION

This preparation is not for administration to humans or animals in the human food chain.

The anti-Syphilis QC2 has been prepared from an anti-Syphilis donation, repeatedly reactive in commercial EIA kits and commercial line blot assay. The reactive donation used to prepare anti-Syphilis QC2 was non-reactive for anti-HIV, HBsAg and anti-HCV using commercial EIA kits. The reactive

donations were then diluted in a pool of defibrinated human plasma samples non-reactive for anti-Syphilis, HBsAg, anti-HCV, anti-HTLV, HIV-1 p24 and anti-HIV using commercial EIA kits. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE

Table 1 gives a summary of the results obtained for anti-Syphilis QC2 17/B713. These results are intended only as a guide to the approximate levels of reactivity to be expected, and may not be exactly reproduced in other laboratories. In each case, at a minimum, three samples of anti-Syphilis QC2 were tested on two separate occasions. The results are expressed as the ratio of mean optical density or other measurement of

the anti-Syphilis response of the QC2 sample, to the kit manufacturer's calculated cut-off.

4. CONTENTS

Country of origin of biological material: United Kingdom.

Ready-to-use reagent

REF QCRSYPHC2 1x4mL Nalgene bottles or 1x7mL Blood Tubes

Defibrinated Plasma 4mL

Bronidox® (Sigma-Aldrich) 0.05% (w/v)

5. STORAGE

o Reagents are to be kept at 2-8°C upon receipt

o Reagents may be stored at 2-8°C until use by date

o For single use only reagents should be divided into measured aliquots of one use and stored below -20°C to avoid freeze/thaw cycles. Once thawed use immediately. Do not refreeze

o Ensure all containers are properly sealed to avoid drying out of the reagent o Avoid microbial contamination of this product as this may alter product performance

o Avoid excessively high temperatures or humidity

6. DIRECTIONS FOR OPENING

Vials have a screw cap; an internal stopper may also be present. The cap should be removed by turning anti-clockwise. Care should be taken to prevent loss of the contents. Please note: If a stopper is present on removal of the cap, the stopper should remain in the vial or be removed with the cap.

7. USE OF MATERIAL

1. Use of this reagent is to be restricted to trained laboratory staff only
2. Use suitable (latex/nitrile) gloves and eye/skin protection
3. Include reagent as a normal sample in routine work list
4. Allow reagent to reach room temperature before use
5. Plot reagent result on a QC chart to monitor performance

The Result Reporting System (RRS) has been developed by the National Institute for Biological Standards and Control (NIBSC) for the data monitoring of its serology and NAT quality control (QC) reagents. These include the Quality Control Reagent Unit (QCRU) and Clinical Virology Network (CVN) reagents. The system has been successfully running for serology assays for several years collecting thousands of data points a year. The system has recently been developed to accept data for Nucleic Acid-based Technologies (NAT) reagents and associated assays.

<https://www.nibsc.org/products/rrs.aspx>

8. STABILITY (Add or amend as necessary)

Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.

Real-Time Stability studies take place to ensure stated stability of this product

9. REFERENCES

1. Levey, S. and Jennings, E.R. (1950) The use of control charts in clinical laboratories. *Am.J.Clin.Pathol.* 20, 1059-1066

10. ACKNOWLEDGEMENTS

EC REP Advena Ltd. Tower Business Centre, 2nd Floor, Swatar, BKR 4013, Malta

11. FURTHER INFORMATION

Further information can be obtained as follows;

This material: enquiries@nibsc.org

WHO Biological Standards:

<http://www.who.int/biologicals/en/>

JCTLM Higher order reference materials:

<http://www.bipm.org/en/committees/jc/jctlm/>

Derivation of International Units:

http://www.nibsc.org/standardisation/international_standards.aspx

Ordering standards from NIBSC:

<http://www.nibsc.org/products/ordering.aspx>

NIBSC Terms & Conditions:

http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET (Add or amend as necessary)

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

Physical and Chemical properties	
Physical appearance: Liquid	Corrosive: No
Stable: Yes	Oxidising: No
Hygroscopic: No	Irritant: No
Flammable: No	Handling: See caution, Section 2
Other (specify):	
Toxicological properties	
Effects of inhalation:	Not established, avoid inhalation
Effects of ingestion:	Not established, avoid ingestion
Effects of skin absorption:	Not established, avoid contact with skin
Suggested First Aid	
Inhalation:	Seek medical advice
Ingestion:	Seek medical advice
Contact with eyes:	Wash with copious amounts of water. Seek medical advice
Contact with skin:	Wash thoroughly with water.

Action on Spillage and Method of Disposal

Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.

15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

Country of origin for customs purposes*: United Kingdom
* Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.
Net weight: 4g
Toxicity Statement: Toxicity not assessed
Veterinary certificate or other statement if applicable.
Attached: No



Table 1:

Results obtained for Anti-Syphilis QC2 (Lot Number 17/B713) using the following EIA kits.

EIA Kit	Method	Cut-Off to test ratio	
		Mean	SD (n-1)
Liaison Treponema Screen Manufacturer: DiaSorin Catalogue Number: 310840 Lot Number: 91063	Automated Protocol	38.4	1.2
Murex ICE* Syphilis Manufacturer: DiaSorin Catalogue Number: 8E04-02 Lot Number: D681010; D716710	Standard Protocol	12.2	0.6
Bioelisa Syphilis 3.0 Manufacturer: Biokit Catalogue Number: 3000-1148 Lot Number: B26659	Standard Protocol	7.8	0.5
Syphilis Ab Manufacturer: Bio-Rad Catalogue Number: 72530 Lot Number: 6L0025	Standard Protocol	16.5	1.6
Enzygnost Syphilis Manufacturer: Siemens Catalogue Number: OWVO115 Lot Number: 46245	Standard Protocol	5.5	0.8
Architect Syphilis TP * Manufacturer: Abbott Catalogue Number: 8D06 Lot Number: 70114L100	Automated Protocol	13.2	0.3
RPR Reditest * Manufacturer: Biokit Catalogue Number: 3000-5550 Lot Number: B26632	Standard Protocol	Neat	N/A
Syphagen TPHA * Manufacturer: Biokit Catalogue Number: 3006-15700 Lot Number: B26435	Standard Protocol	1:640	N/A
Espline TP Manufacturer: Fujirebio Catalogue Number: 219126 Lot Number: TS70306	Standard Protocol	Positive	N/A

* Testing performed by Royal Sussex County Hospital

